Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013 Financial Results on May 10

Progenics Pharmaceuticals to Host Conference Call to Review First Quarter 2013
Financial Results on May 10

TARRYTOWN, N.Y., May 6, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Inc. (Nasdaq:PGNX) announced today that it will host a conference call and
webcast to discuss financial results for the first quarter 2013 on Friday, May
10, 2013 at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001
(international) and reference conference ID 68711767. A live webcast will be
available on the Events section of the Progenics website, www.progenics.com,
and a replay will be available on the website for two weeks.

Progenics Pharmaceuticals, Inc. discovers and develops innovative medicines
for oncology, with a pipeline that includes product candidates in preclinical
through late-stage development. Progenics' first commercial product,
Relistor^® (methylnaltrexone bromide) for opioid-induced constipation, is
marketed and in further development by Salix Pharmaceuticals, Ltd. for markets
worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing
the subcutaneous formulation. For additional information, please visit
www.progenics.com.

(PGNX-G)

CONTACT: Amy Martini
         Corporate Affairs
         (914) 789-2816
         amartini@progenics.com
        
         Kathleen Fredriksen
         Corporate Development
         (914) 789-2871
         kfredriksen@progenics.com

company logo